CareDx Future Growth
Future criteria checks 1/6
CareDx is forecast to grow earnings and revenue by 84% and 10% per annum respectively while EPS is expected to grow by 84.8% per annum.
Key information
84.0%
Earnings growth rate
84.8%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 10.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 12 Sep 2024 |
Recent future growth updates
Recent updates
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Aug 01
CareDx: Benefiting From Some Certainty
Jul 15Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
Apr 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price
Jun 29Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)
May 16CareDx: Shaking Off First-Mover Disadvantage
Oct 18CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
Aug 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 388 | -14 | N/A | N/A | 5 |
| 12/31/2025 | 347 | -37 | N/A | N/A | 8 |
| 12/31/2024 | 325 | -42 | N/A | N/A | 8 |
| 6/30/2024 | 297 | -160 | -22 | -15 | N/A |
| 3/31/2024 | 275 | -183 | -42 | -34 | N/A |
| 12/31/2023 | 280 | -190 | -28 | -18 | N/A |
| 9/30/2023 | 297 | -91 | -14 | -3 | N/A |
| 6/30/2023 | 309 | -84 | -14 | 0 | N/A |
| 3/31/2023 | 320 | -81 | -22 | -3 | N/A |
| 12/31/2022 | 322 | -77 | -50 | -25 | N/A |
| 9/30/2022 | 319 | -74 | -55 | -28 | N/A |
| 6/30/2022 | 315 | -69 | -45 | -21 | N/A |
| 3/31/2022 | 308 | -50 | -34 | -7 | N/A |
| 12/31/2021 | 296 | -31 | -40 | -19 | N/A |
| 9/30/2021 | 276 | -18 | -31 | -16 | N/A |
| 6/30/2021 | 254 | -9 | -27 | -11 | N/A |
| 3/31/2021 | 221 | -14 | -8 | 3 | N/A |
| 12/31/2020 | 192 | -19 | 23 | 33 | N/A |
| 9/30/2020 | 169 | -20 | 14 | 25 | N/A |
| 6/30/2020 | 150 | -19 | 13 | 21 | N/A |
| 3/31/2020 | 139 | -20 | -4 | 0 | N/A |
| 12/31/2019 | 127 | -22 | -6 | -3 | N/A |
| 9/30/2019 | 115 | -21 | -3 | 0 | N/A |
| 6/30/2019 | 102 | -39 | -3 | 0 | N/A |
| 3/31/2019 | 88 | -45 | -13 | -5 | N/A |
| 12/31/2018 | 77 | -47 | -11 | -4 | N/A |
| 9/30/2018 | 66 | -75 | -15 | -8 | N/A |
| 6/30/2018 | 57 | -69 | -17 | -11 | N/A |
| 3/31/2018 | 51 | -59 | N/A | -12 | N/A |
| 12/31/2017 | 48 | -55 | N/A | -14 | N/A |
| 9/30/2017 | 47 | -39 | N/A | -15 | N/A |
| 6/30/2017 | 47 | -29 | N/A | -14 | N/A |
| 3/31/2017 | 46 | -35 | N/A | -17 | N/A |
| 12/31/2016 | 41 | -39 | N/A | -17 | N/A |
| 9/30/2016 | 36 | -29 | N/A | -17 | N/A |
| 6/30/2016 | 31 | -28 | N/A | -19 | N/A |
| 3/31/2016 | 27 | -21 | N/A | -15 | N/A |
| 12/31/2015 | 28 | -14 | N/A | -10 | N/A |
| 9/30/2015 | 29 | -9 | N/A | -6 | N/A |
| 6/30/2015 | 29 | -4 | N/A | -7 | N/A |
| 3/31/2015 | 29 | 0 | N/A | -5 | N/A |
| 12/31/2014 | 27 | 1 | N/A | -3 | N/A |
| 9/30/2014 | 25 | 0 | N/A | -4 | N/A |
| 6/30/2014 | 24 | -2 | N/A | 2 | N/A |
| 3/31/2014 | 23 | -3 | N/A | 1 | N/A |
| 12/31/2013 | 22 | -4 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CDNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CDNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CDNA's revenue (10% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: CDNA's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDNA's Return on Equity is forecast to be high in 3 years time